Europe Cancer Biomarkers Market to Grow with a CAGR of 11.0% during the forecast period 2022 to 2029
Europe
Cancer Biomarkers Market Analysis and Size
Data
Bridge Market Research analyses that the cancer biomarkers market which was USD 4.15 billion in 2022,
would rocket up to USD 9.56 billion by 2030, and is expected to undergo a CAGR
of 11.0% during the forecast period 2023 to 2030. In addition to the insights
on market scenarios such as market value, growth rate, segmentation,
geographical coverage, and major players, the market reports curated by the
Data Bridge Market Research also include depth expert analysis, patient
epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
In addition, competitor analysis is
performed very well in the large scale Europe Cancer
Biomarkers Market report which takes into account
vital aspects about the key players in the market such as strong and weak
points of the competitors and analysis of their strategies with respect to
product and market. Such details about competitive landscape plays very
important role in deciding about the enrichments required in the product
already in the market or the future product. This market report has been framed
after thoroughly understanding business environment which best suits the
requirements of the client. The top notch Europe Cancer
Biomarkers Market business report provides estimations
about the growth rate and the market value based on market dynamics and growth
inducing factors.
Europe
Cancer Biomarkers Market Scope and Segmentation
|
REPORT
METRIC |
DETAILS |
|
Forecast
Period |
2023
to 2030 |
|
Base
Year |
2022 |
|
Historic
Years |
2021
(Customizable to 2015 - 2020) |
|
Quantitative
Units |
Revenue
in USD Billion, Volumes in Units, Pricing in USD |
|
Segments
Covered |
Product
(Consumables, Services, Software, Growth Hormone Therapy), Type (Safety
Biomarkers, Efficacy Biomarkers, Validation Biomarkers, Protein Biomarkers,
Pharmacodynamics Biomarkers, Genetic Biomarkers), Profiling Technologies
(OMICS, Imaging Technology, Immunoassays, Cytogenetics and Bioinformatics),
Service (Sample Preparation, Assay Development, Biomarkers and Testing),
Application (Diagnostics Development, Drug Discovery and Development,
Personalized Medicine, Disease-Risk Assessment, Others), Disease (Prostate
Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, and
Other Diseases), Indication (Cancer, Cardiovascular Disorders, Neurological
Disorders, Immunological Disorders, Others) |
|
Countries
Covered |
Germany,
France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain,
Turkey, Rest of Europe in Europe |
|
Market
Players Covered |
F.
Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.),
Abbott (U.S.), QIAGEN (Germany), PerkinElmer, Inc. (U.S.), Merck KGaA
(Germany) , Bio-Rad Laboratories, Inc. (U.S.) , Enzo Biochem, Inc. (U.S),
Charles River Laboratories (U.S.), Eurofins Scientific (Luxembourg),
Agilent Technologies, Inc. (U.S.), Bruker (U.S.), Siemens (U.S.), Epigenomics
AG (Germany), General Electric (U.S.) |
|
Market
Opportunities |
|
Comments
Post a Comment